Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
Public ClinicalTrials.gov record NCT01061723. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Double Blind-placebo Controlled Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 in Participants With Ankylosing Spondylitis (AS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary objective: \- to evaluate the efficacy of Sarilumab in participants with Ankylosing Spondylitis (AS) using the assessment in AS working group criteria (ASAS) 20% response criteria (ASAS20) Secondary objectives: * to demonstrate that Sarilumab was effective on: * assessment of higher level of response \[ASAS 40% response criteria (ASAS40)\] * partial remission * disease activity * range of motion * Magnetic Resonance Imaging (MRI) of the spine * to assess the safety and tolerability of Sarilumab in participants with AS as well as the pharmacokinetic profile of Sarilumab in participants with AS
Study identification
- NCT ID
- NCT01061723
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 301 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2010
- Primary completion
- May 31, 2011
- Completion
- May 31, 2011
- Last update posted
- Aug 7, 2017
2010 – 2011
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840006 | Birmingham | Alabama | 35205 | — |
| Investigational Site Number 840033 | Anaheim | California | 92801 | — |
| Investigational Site Number 840027 | Los Angeles | California | 90048 | — |
| Investigational Site Number 840007 | San Diego | California | 92108 | — |
| Investigational Site Number 840013 | San Francisco | California | 94143 | — |
| Investigational Site Number 840017 | Upland | California | 91786 | — |
| Investigational Site Number 840009 | Boca Raton | Florida | 33486 | — |
| Investigational Site Number 840001 | Naples | Florida | 34102 | — |
| Investigational Site Number 840032 | Orlando | Florida | 32806 | — |
| Investigational Site Number 840015 | Boise | Idaho | 83702 | — |
| Investigational Site Number 840021 | Rock Island | Illinois | 61201 | — |
| Investigational Site Number 840018 | Kansas City | Kansas | 66160-7321 | — |
| Investigational Site Number 840003 | Wheaton | Maryland | 20902 | — |
| Investigational Site Number 840029 | Worcester | Massachusetts | 01655 | — |
| Investigational Site Number 840008 | Lansing | Michigan | 48823 | — |
| Investigational Site Number 840002 | St Louis | Missouri | 63141 | — |
| Investigational Site Number 840028 | Freehold | New Jersey | 07728 | — |
| Investigational Site Number 840016 | Albany | New York | 12206 | — |
| Investigational Site Number 840036 | Syracuse | New York | 13210 | — |
| Investigational Site Number 840010 | Toledo | Ohio | 43606 | — |
| Investigational Site Number 840005 | Oklahoma City | Oklahoma | 73109 | — |
| Investigational Site Number 840023 | Bethlehem | Pennsylvania | 18015 | — |
| Investigational Site Number 840014 | Duncansville | Pennsylvania | 16635 | — |
| Investigational Site Number 840004 | Dallas | Texas | 75231 | — |
| Investigational Site Number 840030 | Houston | Texas | 77034 | — |
| Investigational Site Number 840034 | Chesapeake | Virginia | 23320 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01061723, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2017 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01061723 live on ClinicalTrials.gov.